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Muscle-in-vein conduit is successfully employed for repairing nerve injuries: the vein prevents muscle fiber dispersion, while the
muscle prevents the vein collapse and creates a favorable environment for Schwann cell migration and axon regrowth. However,
it requires microsurgical skills. In this study we show a simple strategy to improve the performance of a chitosan hollow tube by
the introduction of fresh skeletal muscle fibers.The hypothesis is to overcome the technical issue of the muscle-in-vein preparation
and to take advantage of fiber muscle properties to create an easy and effective conduit for nerve regeneration. Rat median nerve
gaps were repaired with chitosan tubes filled with skeletal muscle fibers (muscle-in-tube graft), hollow chitosan tubes, or autologous
nerve grafts. Our results demonstrate that the fresh skeletalmuscle inside the conduit is an endogenous source of solubleNeuregulin
1, a key factor for Schwann cell survival and dedifferentiation, absent in the hollow tube during the early phase of regeneration.
However, nerve regeneration assessed at late time point was similar to that obtained with the hollow tube. To conclude, the muscle-
in-tube graft is surgically easy to perform and we suggest that it might be a promising strategy to repair longer nerve gap or for
secondary nerve repair, situations in which Schwann cell atrophy is a limiting factor for recovery.
1. Introduction
Currently, the gold standard technique used to repair large
peripheral nerve defects is the autologous nerve graft. How-
ever, this procedure has some well-known disadvantages: the
need of an additional surgery to harvest the donor nerve,
sensory deficits at the donor site, the possibility of neuroma-
in-continuity formation with consequent neuropathic pain,
and the limited availability of donor nerves in terms of num-
ber and diameter [1–3].These limitations inspired researchers
to develop alternative techniques for repairing large nerve
defects.
The use of conduitsmade by nonnervousmaterials (tubu-
lization technique) to bridge nerve gap has beenwidely inves-
tigated and has shown promising results both experimentally
and clinically [2, 4]. Tubular conduits have proven to be
an excellent alternative to autologous nerve grafts because
they act as physical guidance for the regenerating axons and
provide a protective environment for axonal growth by lim-
iting surrounding tissue invasion and by reducing neuroma
and scar tissue formation [5]. Moreover, they facilitate the
accumulation and the concentration of neurotrophic and
neurotropic factors produced by the injured nerve stumps
[6, 7].
Several materials, both of biological and of synthetic
origin, have been used to build tubular conduits [8]. Among
these, muscle-in-vein combined conduits have been exten-
sively and effectively employed to repair injured nerves. The
success of this technique is due to the presence of the vein
that prevents muscle fiber dispersion and scar tissue invasion
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and muscle fibers which prevent the vein collapse and create
a favorable environment for Schwann cell migration and
axonal regrowth [9]. However, the muscle-in-vein graft is
technically challenging and requires microsurgical skills.
Chitosan is a natural polysaccharide that has been
demonstrated to be a good biomaterial with a wide range
of biomedical and tissue engineering applications [10, 11]
due to its biocompatibility, biodegradability, low toxicity,
and bioactivity. In recent studies its regenerative properties
have been demonstrated in both standard and critical length
nerve reconstruction [10, 12, 13]. These promising preclinical
results confirmed that chitosan is a suitable biomaterial for
peripheral nerve regeneration and in 2014 chitosan tubes
have been accepted for clinical use (Reaxon5 Nerve Guide,
Medovent GmbH, Mainz, Germany).
Nevertheless, when more complex lesions occur, such as
long gaps, hollow tubes not always lead to good results and
conduit enrichmentmight create a favorable environment for
nerve regrowth.
In this study we combined the use of a successful conduit
(the chitosan tube) with the promising and simple intra-
luminal structure (fresh longitudinal skeletal muscle fibers)
to evaluate peripheral nerve regeneration after rat median
nerve reconstruction. The hypothesis is to (i) overcome the
technical issue of themuscle-in-vein preparation by the use of
a successful conduit, and to (ii) take advantage of fibermuscle
properties to create a surgically easy and effective conduit for
nerve regeneration.
Rat median nerve gaps were repaired with (i) chitosan
tubes filled with skeletal muscle fibers (muscle-in-tube graft),
(ii) hollow chitosan tubes, or (iii) autologous nerve grafts
(surgical gold standard). Samples harvested at early (1, 7, 14,
and 28 days after nerve repair) time points, together with in
vitro analysis, demonstrated that fresh skeletal muscle pro-
duces and releases solubleNRG1, a key factor for Schwann cell
survival and dedifferentiation present also in the autograft
but absent in the hollow tube in the first phases of nerve
regeneration. However, nerve regeneration assessed at a late
time point (12 weeks) is comparable to that obtained with
the hollow chitosan tube and, as shown in previous studies
[14, 15], with the autograft, in terms of functional recovery,
number and size of regenerating fibers.
2. Methods
2.1. Conditioned Medium for Cell Stimulation and ELISA.
Longitudinal pieces of rat pectoralis majormuscle about 1 cm
long were put in culture immediately after harvesting in a
24-multiwell using 0.5 ml (1, 3 days) or 1 ml (7, 14 days) 2%
FBS DMEM/piece. Supernatant was collected, spun at 3000
rpm at room temperature for 5 minutes, and immediately
frozen in liquid nitrogen for the following ELISA analysis.
To quantify soluble Neuregulin 1 (NRG1) in the muscle
conditioned medium, ELISA analyses (#900-M316, Pepro-
Tech) were performed following manufacturer’s instructions.
2% FBS DMEM was used as background negative control.
To investigate ELISA specificity, recombinant NRG1𝛼 and
NRG1𝛽1 purchased from R&D (#296-HR-050 and #396-HB-
050) were also analyzed.
At the same time points, degenerating muscles were
collected and frozen for RNA extraction and quantitative real
time PCR (qRT-PCR) analyses. As control for RNA analysis,
fresh muscle fibers were also collected. Experiments were
carried out in biological triplicate.
2.2. RNA Isolation, cDNA Preparation, and Quantitative Real
Time PCR. Total RNA was isolated according to the man-
ufacturer’s instructions using TRIzol Reagent (Invitrogen).
Reverse transcription and quantitative real time PCR were
performed and analyzed as previously described [16]. 0.75 𝜇g
of total RNA was retrotranscribed, the cDNA was diluted 10-
fold, and 5 𝜇l (corresponding to 15ng of the starting RNA)
as analyzed for each PCR reaction. The presence of a single
peak corresponding to the required amplicon was verified
and dissociation curves were routinely performed. Technical
and biological triplicates were performed.
As calibrator for relative quantification, the average of
uninjured nerve ΔCt was used for nerve regeneration in vivo
experiments and the average of freshmuscleΔCtwas used for
muscle degradation in vitro analysis.
As housekeeping gene to normalize data, ANKRD27
(Ankyrin repeat domain 27) was used for in vivo nerve
analysis and TBP (TATA Binding protein) was used for in
vitro muscle analysis. Primer sequences for ErbB1, ErbB2,
ErbB3, NRG1 type I/II, type III, 𝛼, 𝛽, type a, type b, type c,
and ANKRD27 were previously published [16]. New unpub-
lished primer sequences were prepared for ErbB4 (acces-
sion number #AY375307.1, amplicon length 103 bp): ErbB4
forward: 5’ AAGTTCTGGATGCGGAAGATGCC-3’ and
ErbB4 reverse: 5’-TTGTTCAGCACACACAGTCCTGG-3’.
For NRG1𝛼 e 𝛽 the forward primer is common: 5'-CGACTG-
GGACCAGCCATCTCATAAAG-3’; NRG1𝛼 reverse: TTG-
CTCCAGTGAATCCAGGTTG (accession number: U02324,
amplicon length: 116 bp); NRG1𝛽 reverse: 5’-AACGATCAC-
CAGTAAACTCATTTGG-3’ (accession number: U02322,
amplicon length: 144 bp). Melting temperature for all primer
pairs was set at 60∘C.
2.3. Surgery. For in vivo study 68 female adult Wistar rats
were used (Harlan, weight: 200-250g). Animals were housed
in a room with controlled temperature and humidity, with
12h of light and 12h of dark and free access to food and
water. Every attempt was made to reduce animal suffering.
All procedures were approved by the Bioethical Committee
of the University of Torino and by the Italian Ministry of
Health. Moreover, these procedures agree with the National
Institutes of Health guidelines, the Italian Law for Care and
Use of Experimental Animals (DL26/14), and the European
Communities Council Directive (2010/63/EU).
During surgical procedures, animals were placed under
general anaesthesia induced by IM injection of Tiletamine +
Zolazepam (Zoletil, 3 mg/kg) and were positioned in supine
position. Using an incision from the nipple to the elbow, the
median nerve was isolated to establish a defect in the middle
of the exposed part, immediately followed by nerve repair
according to the experimental group:
(i) Chitosan-based hollow tube: a nerve segment was
removed and a 10 mm long chitosan tube was used to bridge
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Figure 1: Preparation of the muscle-in-tube graft. A longitudinal piece of the pectoralis major muscle was removed (a) and used to fill the
chitosan conduit (b), to obtain a 10 mm long muscle-in-tube graft (c). The graft was then used to repair a median nerve defect (d). Pictures
showing the regenerated nerves at different time points postsurgery (e). The conduit has been removed and a suture was used to mark the
proximal stump (on the right in the pictures).
the nerve defect by inserting 1 mm of the two nerve ends
inside the conduit. The nerve guide was sutured at each
end.
(ii) Chitosan-based tube filled with fresh skeletal muscle—
“ muscle-in-tube graft”: a nerve segment was removed and a
10 mm long chitosan tube enriched with a longitudinal piece
of the pectoralis major muscle (withdrawn from the same
animal) was used to bridge the nerve defect by inserting 1mm
of the two nerve ends inside the conduit.The nerve guide was
sutured at each end, as shown in Figure 1.
(iii) Autograft: a median nerve segment was cut out,
reversed (distal-proximal), and sutured to the nerve ends
of the same animal. Chitosan-based tubes (Reaxon Nerve
Guide) were supplied by Medovent GmbH, Germany.
Animals were sacrificed by anaesthetic overdose at dif-
ferent times points: 1 day (only autograft and muscle-in-tube
graft) and 7, 14, and 28 days for early time point analysis; 1
day hollow chitosan tube graft was not analyzed, because it is
colonized only by fluid and it was not possible to withdraw it.
For late time point analysis (only hollow tube and muscle-in-
tube), animals were sacrificed 12 weeks after the surgery. Data
about autograft 12 weeks after surgery are already present in
literature [14, 15]. For each time point (1, 7, 14, and 28 days)
n=4 samples for each experimental group were harvested for
biomolecular analysis and n=1 for qualitative morphological
analysis (7, 14, and 28 days). For morphometrical analysis, 12
weeks regenerated distal stumps were harvested (n=5).
Healthy median nerve segments and healthy pectoralis
major muscles from other rats were also harvested as control
in the qRT-PCR analysis.
2.4. Grasping Test. The grasping test was performed to
estimate the functional recovery after nerve reconstruction.
The analysis was carried out before animal sacrifice (12 weeks
after nerve repair) following the same procedure previously
described [17]. Rats were acclimatize before the testing. Each
animal was tested three times and the average value was
recorded.
2.5. Resin Embedding, High Resolution Light Microscopy, and
Electron Microscopy Analysis. Samples corresponding to the
grafted region (the autologous nerve and the filler of the
chitosan tubes) harvested 7, 14, and 28 days after repair and
the distal portion of regenerated median nerve, harvested
12 weeks after repair, were processed for resin embedding
as previously described and semithin and ultrathin sections
were cut for light and electron microscopy analysis [14].
2.6. Morphometrical Analysis. The quantification of myeli-
nated nerve fibers was performed on electron microscopy
micrographs. Briefly, on one randomly selected ultrathin
section, 15-20 fields were chosen using a systematic random
sampling protocol, as earlier described [18], with amagnifica-
tion of 4000X. In each sampling field, a two-dimensional (2D)
dissector procedure was used [18]. Mean fiber density, total
fiber number, fiber and axon diameter, myelin thickness, and
g-ratio were then estimated. The total cross-sectional area of
the whole nerve was measured on the toluidine-blue-stained
semithin section.
2.7. Statistical Methods. For statistical analysis IBM SPSS
Statistics 22.0 software was used. Data were expressed as
mean ± standard error of the mean (SEM). Data sets
containing two groups were analyzed through two-tailed
Student’s t-test, while data sets with more than two groups
were processed with one-way analysis of variance (ANOVA)
with Bonferroni correction to compare at the different time
points the three experimentalmodels of nerve repair andwith
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Figure 2: Degenerating muscle expresses NRG1. (a) qRT-PCR showing the relative quantification (-ΔΔCt = log2fold change) of the different
NRG1 isoforms in in vitro degenerating muscle. TBP was used as housekeeping gene to normalize data. (b) ELISA data showing NRG1𝛽1
release in the medium of degenerating muscles. Data are expressed as mean ± SEM. Asterisks denote significant differences between
degenerating muscles and the healthy muscle (a) or between the released NRG1 amounts at the different time points (b), ∗p ≤ 0.05, ∗∗p ≤
0.01, and ∗∗∗p ≤ 0.001.
two-way ANOVA to analyze the influence of the two factors
(experimental model of nerve repair and time after repair).
3. Results
3.1. In Vitro Analysis: Soluble Neuregulin 1 Is Expressed
and Released by in Vitro Degenerating Muscles. To evaluate
the expression level of the different Neuregulin 1 (NRG1)
isoforms in degenerating muscles, longitudinal pieces of
the pectoralis major muscle were put in culture in 0.5 ml
2% FBS medium immediately after harvesting. At different
time points (1, 3, 7, and 14 days) total RNA was extracted
from in vitro degenerating muscles and from control healthy
muscles and the expression level of different NRG1 isoforms
was analyzed by quantitative real time PCR, discriminating
among soluble and transmembrane, 𝛼 and 𝛽, type a, type b,
and type c isoforms.Data analysis showed that, during in vitro
degradation, soluble isoforms were strongly and significantly
upregulated and that soluble upregulated isoforms belonged
to 𝛼 and 𝛽, type a, and type b isoforms; transmembrane
and type c isoforms were also upregulated, although with a
high threshold cycle (Ct) indicative of a low expression level
(Figure 2(a)).
Conditioned medium was collected and analyzed by
ELISA to quantify soluble NRG1 release. ELISA was per-
formed on 50 𝜇l muscle conditioned medium collected after
1, 3, 7, and 14 days of in vitro culture. To investigate if
ELISA antibodies were able to recognize both NRG1𝛼 and
NRG1𝛽, additional standard curves were performed using
recombinant proteins; nevertheless, only NRG1𝛽 isoforms
were recognized (data not shown). ELISA data analysis
showed that muscle was able to release soluble NRG1𝛽 in the
medium (1.721 ng/ml ± 0.231 after 24 hours, Figure 2(b)).
3.2. In Vivo Analysis. To verify the effectiveness of the mus-
cle-in-tube graft to repair rat median nerve gaps, we com-
pared thismethodwith hollow chitosan tubes and autologous
nerve graft.
3.2.1. Short-Term Analysis of Regenerated Nerve: Qualitative
Morphology. To observe the qualitative morphology of the
nerve in the early stages of regeneration, high resolution
light micrographs of toluidine-blue stained semithin sections
were taken at short-term time points postsurgery (7, 14 and
28 days). Images were gathered inside the different grafts,
both proximally and distally, to follow nerve regeneration
alongside the conduits (Figure 3).
Nerves repaired with the autograft (positive control)
showed an early regeneration, as expected (Figure 3(a)). 7
days after implantation, the nerve fibers inside the graft
underwent Wallerian degeneration and the graft was filled
with axons andmyelin debris. After 14 days regenerated fibers
were already present in the proximal part of the graft, while in
the distal part endoneurial tubes were ready to be colonized
by regrowing axons. Finally, after 28 days the whole graft was
colonized by regenerated fibers.
Regeneration inside the hollow chitosan tube is slower
when compared to the autograft (Figure 3(b)). Few days
after implantation, extracellular matrix and fluid containing
inflammatory cells filled the conduit. After 14 days, several
cell types colonize the conduit and only after 28 days were
the myelinated fibers detectable inside the conduit. Regen-
erated fibers were compacted in the central part of the tube
(Figure 3(b)).
In the muscle-in-tube graft, longitudinal muscle fibers
were inserted inside the chitosan conduit to provide a
physical and trophic scaffold for axon and cell growth
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Figure 3: Representative high resolution light images of toluidine-blue stained semithin transverse sections of regenerated median nerve
repaired with autograft (a), hollow chitosan tube (b), or muscle-in-tube graft (c). Images were taken inside the grafts, both proximally (left
columns, about 1,5 mm from the proximal suture point) and distally (right columns, about 1,5 mm from the distal suture point), at different
time points (7, 14, 28 days after repair). Bar: 40 𝜇m.
(Figure 3(c)). 7 days after nerve repair, big muscle fibers
were clearly detectable inside the graft, together with dif-
ferent cell types. After 14 days, muscle fibers appeared
smaller, showing that they were undergoing progressive
degeneration over time. Few myelinated fibers organized
in small fascicles were detectable. Finally, 28 days after
implantation, the conduit was colonized by a high num-
ber of myelinated fibers organized in fascicles. Among
nerve fascicles, small degenerating muscle fibers were still
visible.
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Figure 4: Quantitative analysis of SC marker expression. Relative quantification (-ΔΔCt = log2fold change) of S100 (a), GFAP (b), and p75
(c) was evaluated by qRT-PCR. Both healthy nerves and healthy muscle fibers were analyzed and shown in the figures (green and red lines,
respectively). ANKRD27 was used as housekeeping gene to normalize data. Values in the graphics are expressed as mean ± SEM. One-way
ANOVA was carried out; asterisks (∗) denote statistically significant differences between autograft and hollow chitosan tube groups; hashes
(#) between autograft andmuscle-in-tube groups; dollars ($) between hollow chitosan tube andmuscle-in-tube graft. ∗/#/$p ≤ 0.05, ∗∗/##/$$p ≤
0.01, and ∗∗∗/###/$$$p ≤ 0.001. Two-way ANOVA is shown in Table S1.
3.2.2. Short-TermAnalysis of Regenerated Nerve: Biomolecular
Evaluation. At different time points after nerve reconstruc-
tion (1, 7, 14, and 28 days), three Schwann cell markers
(S100, p75, GFAP), ErbB receptors, and different NRG1
isoforms were examined by qRT-PCR in the grafts of the
three experimental groups (Figures 4 and 5). For the hollow
tube, we analyzed the samples starting from day 7 after repair,
because 1 day after repair the tube was colonized only by
fluid material and was not possible to withdraw and analyze
it. Because the hollow chitosan tube and the muscle-in-tube
graft at time zero do not contain Schwann cells, the starting
point of expression analysis should be considered 7 days for
the hollow chitosan tube and 1 day for muscle-in-tube graft.
The expression of Schwann cell markers S100 and GFAP
was significantly lower in hollow chitosan tube and muscle-
in-tube compared to both the autograft and the healthy
nerves. After 28 daysmuscle-in-tube graft still showed a lower
expression of these two markers (Figures 4(a) and 4(b)).
p75 expression was significantly higher in the autograft
samples at the different time points, while after 28 days no
differences among the three repair experimental models were
detectable (Figure 4(c)).
Then, ErbB receptors and NRG1 isoforms were analyzed.
ErbB1 expression level in the muscle-in-tube samples was
downregulated after injury and repair and was lower than
in the hollow tube and in the autograft samples, where the
expression was similar (Figure 5(a)).
ErbB2 expression in the muscle-in-tube samples was
strongly and stably upregulated at 7 and 14 days after injury
relatively both to the healthy nerve and muscle and to the
autograft and the hollow chitosan groups. At day 14 the
autograft showed an expression level higher than the empty
chitosan group (Figure 5(b)).
ErbB3 expression in the chitosan tube and in the muscle-
in-tube after injury was lower than in the autograft samples.
28 days after injury ErbB3 expression in the hollow chitosan
samples was similar to the autograft and higher than the
muscle-in-tube samples (Figure 5(c)).
ErbB4 expression is significantly lower in the muscle-
in-tube samples—relatively to both healthy muscle and
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Figure 5: Continued.
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Figure 5: Quantitative analysis of theNRG1/ErbB system expression. qRT-PCR showing the relative quantification (-ΔΔCt = log2fold change)
of ErbB receptors (a-d) and the different NRG1 isoforms (e-j). Both healthy nerves and healthy muscle fibers were analyzed and shown in the
figures (green and red lines, respectively). ANKRD27 was used as housekeeping gene to normalize data. Values in the graphics are expressed
as mean ± SEM. One-way ANOVA was carried out; asterisks (∗) denote statistically significant differences between autograft and hollow
chitosan tube groups; hashes (#) between autograft and muscle-in-tube groups; dollars ($) between hollow chitosan tube and muscle-in-tube
graft. ∗/#/$p ≤ 0.05, ∗∗/##/$$p ≤ 0.01, and ∗∗∗/###/$$$p ≤ 0.001. Two-way ANOVA is shown in Table S1.
nerve—already 1 day after injury and remained really low
until 28 days. In the hollow chitosan samples ErbB4 expres-
sion was similar to the muscle-in-tube samples, while in
the autograft ErbB4 expression decreased after injury but
was higher than the muscle-in-tube graft and the hollow
chitosan samples. 28 days after injury only hollow chitosan
samples showed an expression level similar to the autograft
(Figure 5(d)).
NRG1 expression analysis is really complex, because
each primer pair amplifies a single isoform, but soluble
and transmembrane isoforms can be type 𝛼 or type 𝛽, and
type a, b, or c. Transmembrane NRG1 expression was also
analyzed but not shown, because its expression level is barely
detectable, being this isoform expressed mainly by the axon
and not by Schwann cells.
Autograft showed a strong early upregulation (1 day) of
the different NRG1 isoforms (except for NRG1c) followed
by a return to values similar to control nerves. On the
contrary, NRG1c was downregulated from the 14th day
(Figures 5(e)–5(j)).
In the first days after implantation, the hollow chitosan
tube is filled by cells which do not express NRG1 or that
express it at low level; indeed, at day 7 mRNA expression of
most NRG1 isoforms was similar or lower to control nerve
values. At day 14 NRG1 𝛼 started to be overexpressed and was
still upregulated after 28 days (Figures 5(e)–5(j)).
Finally, muscle-in-tube graft showed an expression pat-
tern very similar to that of the autograft: all soluble NRG1
isoforms showed a strong peak 1 day after implantation
(except for NRG1c) and then the upregulation of most of
them was still high at 7 and 14 days, returning to control
values after 28 days (except for NRG1 𝛼, that was still
upregulated also after 28 days) (Figures 5(e)–5(j)).
Overall, the upregulation peak of NRG1 isoforms in
the hollow chitosan tube started only 14 days after injury
and is lower than muscle-in-tube graft. Intriguingly, the
upregulation at day 1 of soluble NRG1 (𝛼 and c isoforms)
in muscle-in-tube samples was stronger than in autograft
samples.
Two-way ANOVA was carried out for all analyzed genes
to evaluate the effect on their expression of the different
repair experimental models and of the time after repair
(see Figure S1). For all genes, statistical analysis with two-
way ANOVA revealed significant main effects of the repair
experimental model (dF=2, P<0.0001) and of the time (dF=4,
P<0.0005); interaction between the 2 factors was revealed to
be statistically significant (dF=7, P<0.05) for all genes except
ErbB4 (P=0,056) and NRG1c (P=0.053).
3.2.3. Long-Term Analysis of Regenerated Nerve: Functional,
Morphological, and Morphometrical Analyses. To determine
whether the presence of fresh muscle fibers inside the
chitosan tube influences nerve regeneration, we performed a
functional test (grasping test) and morphometrical analysis
on the nerve segment distal to the graft 12 weeks after
nerve reconstruction (Figure 6). Analyses were performed at
electron microscopy level to enable accurate identification of
all myelinated nerve fibers.
The functional test performed at week 12 after repair did
not show statistical differences between the hollow chitosan
tube and the muscle-in-tube groups (Figure 6(a)).
Results of the quantitative analysis performed on regen-
erated nerve fibers show no significant differences in all the
analyzed parameters between the two experimental groups
(Figures 6(b)–6(f)), as showed also by representative images
(Figure 6(g)).The frequency distribution of nerve fiber diam-
eters showed a shift of themuscle-in-tube histograms towards
bigger size (Figure 6(h)). Finally, scatter plots displaying
g-ratios of individual fibers in relation to respective axon
diameter showed no differences between groups (Figure 6(i)).
4. Discussion
The use of hollow conduits to repair nerve defects is a
valid alternative technique to autograft because of their
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Figure 6: Functional, morphological, and morphometrical analyses of long-term regenerated nerves after hollow tube or muscle-in-tube
(MIT) graft primary repair. (a) Histograms showing the result of the grasping test, performed 12 weeks after nerve repair. (b-f) Histograms
of morphometrical analysis of the regenerated myelinated fibers. Analyses were performed 3 mm distal to the graft: (b) cross-sectional area
of the whole nerve section, (c) myelinated fiber density, (d) total number of myelinated fibers, (e) size parameters (axon and fiber diameter,
myelin thickness), and (f) g-ratio. Values in the graphics are expressed as mean + SEM. (g) Representative electron microscopy images of the
regenerated distal part of the two experimental groups. Bar: 2 𝜇m. (h) Frequency distribution histograms of myelinated fiber diameters. The
two lines are the fitting lines of the distribution. (i) Scatter plots showing g-ratio of individual myelinated axons as a function of axon diameter.
Regression lines, their equations, and R2 are also shown. Both (h) and (i) data were obtained by pooling all the values from all animals for
each experimental group; hollow tube: n=830; muscle-in-tube graft: n=777.
well-demonstrated advantages, and in the last years several
kinds of conduits have been proposed for their use in clinic.
However, the efficiency of hollow conduits is still insuffi-
cient, especially for large nerve gap, probably due to an inade-
quate formation of the extracellular matrix, thus limiting cell
migration and axonal regrowth [6]. Anumber of intraluminal
fillers of both biological and synthetic nature have been
proposed to enrich hollow conduits [19]. Skeletal muscle
fibers have been demonstrated to be a suitable intraluminal
filler for several reasons. Firstly, the three-dimensional (3D)
environment provided by the muscle basal lamina acts as
a useful scaffold for growing axons and for migrating cells
(Schwann cells, fibroblasts, and endothelial cells) [7]. Second,
the muscle tissue is readily available at the nerve injury site
and can be easily translated into clinical practice.
In 1993, Brunelli et al. [20] described an innovative
biological conduit made by a vein segment filled with fresh
skeletal muscle fibers (muscle-in-vein combined conduit).
This technique result was experimentally successful and was
therefore translated also to the clinic to treat certain cases of
peripheral nerve injuries [21–23]. Nevertheless, the muscle-
in-vein graft is not easy to perform and only few surgeons
possess the technical skills necessary to build it.
To overcome this technical issue, the muscle tissue can
be introduced inside a tubular conduit. However, so far,
the placement of denatured skeletal muscle tissue [24–
29] or fresh skeletal muscle fibers [30, 31] inside different
kinds of tubular conduits (collagen, poly L-lactic acid and
∈-caprolactone–PLAC, or DL-lactide and ∈-caprolactone
[p(DLLA-CL)]) has shown contrasting results in terms of
nerve regeneration and functional recovery.
In this study we used a conduit made of chitosan (Reaxon
Nerve Guide), that has been shown to promote successful
nerve regeneration [12], combined with fresh longitudinal
skeletal muscle fibers. The hypothesis is (i) to overcome the
technical issue of the muscle-in-vein preparation and (ii) to
take advantage of fibermuscle properties to create a surgically
easy and effective conduit for nerve regeneration.
We used the fresh muscle tissue because it has been
demonstrated that muscle cells produce and release factors
that contribute to the survival of motoneurons in vitro [32].
Among released factors there are brain-derived neurotrophic
factor, bone morphogenetic protein 6, cardiotrophin 1, glial
cell-derived neurotrophic factor, heparan sulfate, hepatocyte
growth factor, insulin-like growth factors, neurotrophin 3,
neurotrophin 4, and vascular endothelial growth factor [32].
Here we focused our attention on Neuregulin 1 (NRG1),
because it is known to be one of the most important fac-
tors regulating Schwann cell activity (survival, proliferation,
dedifferentiation, and migration) and, therefore, it is a key
factor for peripheral nerve regeneration. In vitro experiments
performed in this study demonstrated that (i) skeletal muscle
fibers upregulate the expression of soluble NRG1 mRNA
while they are degenerating and that (ii) the soluble NRG1
protein produced by the muscle is released in the medium.
Our results are in accordance with previous studies, showing
a significant upregulation of soluble NRG1 after skeletal
muscle denervation [33] and an increase in NRG1 mRNA
in the muscle-in-vein combined grafts at early regeneration
stages, while muscle is degenerating [34]. However, as far as
we know, this is the first study showing the release of soluble
NRG1 protein in the environment.
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Taken together, these results show that the fresh skeletal
muscle can be an endogenous source of the gliotrophic factor
NRG1. For this reason, we moved to in vivo experiments
using the rat median nerve experimental model for a primary
repair of short gaps.The nerve gap has been repaired with the
chitosan nerve guide (Reaxon Nerve Guide), filled with fresh
skeletal muscle fibers (muscle-in-tube graft), and compared
with the hollow one.
Our in vivo experiments aimed to (i) evaluate the different
behavior of regenerating fibers inside the conduits (muscle-
in-tube versus hollow tube) in terms of gene expression and
axonal regrowth in the early stages of nerve regeneration
(up to 28 days) and to (ii) investigate whether the conduit
filled with fresh skeletal muscle fibers could improve nerve
regeneration at later time points in terms of functional
recovery and regeneration degree (12 weeks).
Our results indicate that muscle-in-tube graft promotes
nerve regeneration. With respect to functional recovery and
quantitative morphometry, no significant differences were
observed between the two experimental groups at 12 weeks
after surgery, suggesting that both conduits are effective for
repairing peripheral nerve defects in this experimentalmodel
(short gap primary repair). The comparison of morphome-
trical data obtained in this study with our previous data
obtained using autograft [14] shows that the regenerated fiber
number is slightly lower in the two experimental groups
compared to autograft group, but the size parameters are
very similar. Also, functional recovery reached similar values
between the two chitosan experimental groups and the
autograft [15], confirming the efficiency of themuscle-in-tube
graft in promoting nerve regeneration.
The mRNA analysis of these samples is really complex.
Indeed, muscle-in-tube samples at early time points (1 day
and 7 days after injury and repair) are in fact mostly muscles
and for this reason we have to compare them also with the
muscle, not only with the nerve. Then, step by step, the
muscle mRNA percentage decreases, while the nerve mRNA
percentage increases. Consequently, although healthy nerves
were used as a common calibrator for the three experimental
groups, both healthy nerves and healthy muscle fibers were
analyzed and shown in the figures. Also hollow chitosan
tubes represent a complex model, although in a different
way: they need to be filled by migrating cell populations
and for this reason the possible gene downregulation in
the first time point (7 days) is only apparent, because at
time zero they are just empty tubes. Therefore, 7 days
should be considered the expression starting point for these
samples.
mRNA analysis, performed inside the conduits at shorter
time points, demonstrates that Schwann cell markers S100,
p75, and GFAP are less expressed both in the hollow chitosan
tube and in themuscle-in-tube graftwhen comparedwith the
autograft.This is an expected result because the chitosan tube
(empty or filled with muscle fibers) needs to be colonized
by Schwann cells, whereas the autograft already contains
Schwann cells that start to dedifferentiate immediately after
repair. The slight (and insignificant) different expression
between hollow chitosan tube andmuscle-in-tube graftmight
be explained by the fact that in the muscle-in-tube graft
the nerve RNA is “diluted” by the presence of muscle
RNA.
Interestingly, hollow chitosan tube and muscle-in-tube
graft differed greatly in terms of NRG1 expression: different
isoforms of soluble NRG1 are highly expressed in the muscle-
in-tube early after nerve repair, whereas no NRG1 expression
is seen in the hollow chitosan tube. The NRG1 expression
pattern observed in muscle-in-tube samples is very similar
to that observed in autograft samples, in which NRG1 is
upregulated by Schwann cells that colonize the graft. A
similar expression pattern has also been described in other
experimental models, such as crush injury and end-to-
end repair [16], suggesting that soluble NRG1 isoforms are
involved in the response to nerve injury, stimulating Schwann
cell survival and promoting axon regrowth.
5. Conclusions
Our results show that the muscle-in-tube graft promotes
nerve regeneration as efficiently as the hollow chitosan tube
and that the fresh skeletal muscle inserted inside the chitosan
conduit may be an endogenous source of soluble NRG1, a
source that is absent in the hollow tube. We recently showed
that, after prolonged degeneration of the median nerve distal
stump, Schwann cells undergo atrophy and downregulate the
expression of soluble NRG1. Even after the cross-suture with
the freshly axotomized ulnar nerve proximal stump, NRG1
remains at very low expression level and nerve regeneration
results are impaired [35]. Therefore, we suggest that soluble
NRG1 supplied by fresh skeletal muscle-enriched conduit
might be more useful to improve nerve regeneration in
advanced experimental models, such as a longer gap or
delayed (secondary) nerve repair.
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Figure S1: For quantitative real time PCR data, the effect
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the two factors (repair ∗ time) were analyzed by two-way
ANOVA test. Analysis of all genes showed highly significant
main effects of repair and time. The interaction between the
two factors is highly significant for most genes (dF = degrees
of freedom, P = P value). (Supplementary Materials)
References
[1] A. Faroni, S. A. Mobasseri, P. J. Kingham, and A. J. Reid,
“Peripheral nerve regeneration: experimental strategies and
future perspectives,” Advanced Drug Delivery Reviews, vol. 82-
83, pp. 160–167, 2015.
[2] P. Konofaos and J. P. ver Halen, “Nerve repair by means of
tubulization: past, present, future,” Journal of Reconstructive
Microsurgery, vol. 29, no. 3, pp. 149–164, 2013.
[3] P. A. Wieringa, A. R. Gonc¸alves de Pinho, S. Micera, R. J. van
Wezel, and L.Moroni, “NerveRepair: BiomimeticArchitectures
for Peripheral Nerve Repair: A Review of Biofabrication Strate-
gies (Adv. Healthcare Mater. 8/2018),” Advanced Healthcare
Materials, vol. 7, no. 8, p. 1870035, 2018.
[4] S. Ichihara, Y. Inada, and T. Nakamura, “Artificial nerve tubes
and their application for repair of peripheral nerve injury: an
update of current concepts,” Injury, vol. 39, no. 4, pp. S29–S39,
2008.
[5] L. A. Pfister, M. Papaloı¨zos, H. P.Merkle, and B. Gander, “Nerve
conduits and growth factor delivery in peripheral nerve repair,”
Journal of the Peripheral Nervous System, vol. 12, no. 2, pp. 65–
82, 2007.
[6] W. Daly, L. Yao, D. Zeugolis, A. Windebank, and A. Pandit,
“A biomaterials approach to peripheral nerve regeneration:
bridging the peripheral nerve gap and enhancing functional
recovery,” Journal of the Royal Society Interface, vol. 9, no. 67,
pp. 202–221, 2012.
[7] M. F. Meek, A. S. P. Vareja˜o, and S. Geuna, “Use of skeletal mus-
cle tissue in peripheral nerve repair: Review of the literature,”
Tissue Engineering Part A, vol. 10, no. 7-8, pp. 1027–1036, 2004.
[8] K. Belanger, T. M. Dinis, S. Taourirt, G. Vidal, D. L. Kaplan, and
C. Egles, “Recent Strategies in Tissue Engineering for Guided
Peripheral Nerve Regeneration,” Macromolecular Bioscience,
vol. 16, no. 4, pp. 472–481, 2016.
[9] S. Raimondo, S. Nicolino, P. Tos et al., “Schwann cell behavior
after nerve repair by means of tissue-engineered muscle-vein
combined guides,” Journal of Comparative Neurology, vol. 489,
no. 2, pp. 249–259, 2005.
[10] K. Haastert-Talini, S. Geuna, and L. B. Dahlin, “Chitosan tubes
of varying degrees of acetylation for bridging peripheral nerve
defects,” Biomaterials, vol. 34, no. 38, pp. 9886–9904, 2013.
[11] L. Zheng andH.-F. Cui, “Use of chitosan conduit combinedwith
bonemarrowmesenchymal stem cells for promoting peripheral
nerve regeneration,” Journal of Materials Science: Materials in
Medicine, vol. 21, no. 5, pp. 1713–1720, 2010.
[12] M. Bąk, O. Gutlowska, E. Wagner, and J. Gosk, “The role
of chitin and chitosan in peripheral nerve reconstruction,”
Polymers in Medicine, vol. 47, no. 1, pp. 43–47, 2017.
[13] C. Meyer, L. Stenberg, F. Gonzalez-Perez et al., “Chitosan-film
enhanced chitosan nerve guides for long-distance regeneration
of peripheral nerves,” Biomaterials, vol. 76, pp. 33–51, 2016.
[14] G. Ronchi, S. B. Jager, C. B. Vaegter, S. Raimondo, M. G.
Giacobini-Robecchi, and S. Geuna, “Discrepancies in quanti-
tative assessment of normal and regenerated peripheral nerve
fibers between light and electron microscopy,” Journal of the
Peripheral Nervous System, vol. 19, no. 3, pp. 224–233, 2014.
[15] G. Gambarotta, D. Pascal, G. Ronchi et al., “Local delivery of the
Neuregulin1 receptor ecto-domain (ecto-ErbB4) has a positive
effect on regenerated nerve fibermaturation,”GeneTherapy, vol.
22, no. 11, pp. 901–907, 2015.
[16] G. Ronchi, K. Haastert-Talini, B. E. Fornasari, I. Perroteau, S.
Geuna, and G. Gambarotta, “The Neuregulin1/ErbB system is
selectively regulated during peripheral nerve degeneration and
regeneration,” European Journal of Neuroscience, vol. 43, no. 3,
pp. 351–364, 2016.
[17] G. Ronchi, S. Nicolino, S. Raimondo et al., “Functional and
morphological assessment of a standardized crush injury of the
rat median nerve,” Journal of NeuroscienceMethods, vol. 179, no.
1, pp. 51–57, 2009.
[18] S. Geuna, P. Tos, B. Battiston, and R. Guglielmone, “Verification
of the two-dimensional disector, a method for the unbiased
estimation of density and number of myelinated nerve fibers in
peripheral nerves,”Annals of Anatomy, vol. 182, no. 1, pp. 23–34,
2000.
[19] V. Carriel, M. Alaminos, I. Garzo´n, A. Campos, and M.
Cornelissen, “Tissue engineering of the peripheral nervous
system,” Expert Review of Neurotherapeutics, vol. 14, no. 3, pp.
301–318, 2014.
[20] G. A. Brunelli, B. Battiston, A. Vigasio, G. Brunelli, and D.
Marocolo, “Bridging nerve defects with combined skeletal
muscle and vein conduits,”Microsurgery, vol. 14, no. 4, pp. 247–
251, 1993.
[21] M. Ignazio and V. Adolfo, “Muscle-in-vein nerve guide for
secondary reconstruction in digital nerve lesions,” Journal of
Hand Surgery, vol. 35, no. 9, pp. 1418–1426, 2010.
[22] J. L. Schiefer, L. Schulz, R. Rath, S. Stahl, H.-E. Schaller, and
T. Manoli, “Comparison of short- with long-term regeneration
results after digital nerve reconstruction with musclein-vein
conduits,” Neural Regeneration Research, vol. 10, no. 10, pp.
1674–1677, 2015.
[23] P. Tos, B. Battiston, D. Ciclamini, S. Geuna, and S. Artiaco,
“Primary repair of crush nerve injuries by means of biological
tubulization with muscle-vein-combined grafts,” Microsurgery,
vol. 32, no. 5, pp. 358–363, 2012.
[24] O. Alluin, C. Wittmann, T. Marqueste et al., “Functional
recovery after peripheral nerve injury and implantation of a
collagen guide,” Biomaterials, vol. 30, no. 3, pp. 363–373, 2009.
[25] U. Dornseifer, A. M. Fichter, S. Leichtle et al., “Peripheral
nerve reconstruction with collagen tubes filled with denatured
autologousmuscle tissue in the ratmodel,”Microsurgery, vol. 31,
no. 8, pp. 632–641, 2011.
[26] M. F. Meek, W. F. A. den Dunnen, J. M. Schakenraad, and P.
H. Robinson, “Evaluation of functional nerve recovery after
reconstruction with a poly (DL-lactide-epsilon-caprolactone)
nerve guide, filled with modified denatured muscle tissue,”
Microsurgery, vol. 17, no. 10, pp. 555–561, 1997.
[27] M. F. Meek, W. F. A. Den Dunnen, J. M. Schakenraad, and
P. H. Robinson, “Evaluation of several techniques to modify
denaturedmuscle tissue to obtain a scaffold for peripheral nerve
regeneration,” Biomaterials, vol. 20, no. 5, pp. 401–408, 1999.
BioMed Research International 13
[28] M. F. Meek, P. H. Robinson, I. Stokroos, E. H. Blaauw, G.
Kors, and W. F. A. den Dunnen, “Electronmicroscopical eval-
uation of short-term nerve regeneration through a thin-walled
biodegradable poly(DLLA-epsilon-CL) nerve guide filled with
modified denatured muscle tissue,” Biomaterials, vol. 22, no. 10,
pp. 1177–1185, 2001.
[29] N. L. Mligiliche, Y. Tabata, M. Kitada et al., “Poly lactic acid-
caprolactone copolymer tube with a denatured skeletal muscle
segment inside as a guide for peripheral nerve regeneration:
A morphological and electrophysiological evaluation of the
regenerated nerves,” Anatomical Science International, vol. 78,
no. 3, pp. 156–161, 2003.
[30] A. S. P. Vareja˜o, A. M. Cabrita, S. Geuna et al., “Func-
tional assessment of sciatic nerve recovery: Biodegradable
poly (DLLA-epsilon-CL) nerve guide filled with fresh skeletal
muscle,”Microsurgery, vol. 23, no. 4, pp. 346–353, 2003.
[31] A. S. P. Vareja˜o, A. M. Cabrita, M. F. Meek, M. Fornaro, S.
Geuna, and M. G. Giacobini-Robecchi, “Morphology of nerve
fiber regeneration along a biodegradable poly (DLLA-epsilon-
CL) nerve guide filled with fresh skeletal muscle,”Microsurgery,
vol. 23, no. 4, pp. 338–345, 2003.
[32] J. V. Montoya G., J. J. Sutachan, W. S. Chan, A. Sideris, T. J.
J. Blanck, and E. Recio-Pinto, “Muscle-conditioned media and
cAMP promote survival and neurite outgrowth of adult spinal
cord motor neurons,” Experimental Neurology, vol. 220, no. 2,
pp. 303–315, 2009.
[33] S. Nicolino, A. Panetto, S. Raimondo et al., “Denervation
and reinnervation of adult skeletal muscle modulate mRNA
expression of neuregulin-1 and ERBB receptors,” Microsurgery,
vol. 29, no. 6, pp. 464–472, 2009.
[34] S. Nicolino, S. Raimondo, P. Tos et al., “Expression of 𝛼2a-2b
neuregulin-1 is associated with early peripheral nerve repair
along muscle-enriched tubes,” NeuroReport, vol. 14, no. 11, pp.
1541–1545, 2003.
[35] G. Ronchi, M. Cillino, G. Gambarotta et al., “Irreversible
changes occurring in long-termdenervated Schwann cells affect
delayed nerve repair,” Journal of Neurosurgery, vol. 127, no. 4, pp.
843–856, 2017.
Stem Cells 
International
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
MEDIATORS
INFLAMMATION
of
Endocrinology
International Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Disease Markers
Hindawi
www.hindawi.com Volume 2018
BioMed 
Research International
Oncology
Journal of
Hindawi
www.hindawi.com Volume 2013
Hindawi
www.hindawi.com Volume 2018
Oxidative Medicine and 
Cellular Longevity
Hindawi
www.hindawi.com Volume 2018
PPAR Research
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2013www.hindawi.com
The Scientific 
World Journal
8
Immunology Research
Hindawi
www.hindawi.com Volume 2018
Journal of
Obesity
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
 Computational and  
Mathematical Methods 
in Medicine
Hindawi
www.hindawi.com Volume 2018
Behavioural 
Neurology
Ophthalmology
Journal of
Hindawi
www.hindawi.com Volume 2018
Diabetes Research
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Research and Treatment
AIDS
Hindawi
www.hindawi.com Volume 2018
Gastroenterology 
Research and Practice
Hindawi
www.hindawi.com Volume 2018
Parkinson’s 
Disease
Evidence-Based 
Complementary and
Alternative Medicine
Volume 2018
Hindawi
www.hindawi.com
Submit your manuscripts at
www.hindawi.com
